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paclitaxel-eluting stents for the treatment of femoro-popliteal (FP)
occlusive disease. However, the external validity of trial results may
be restricted to less complex FP lesions, and limited data on outcomes
of pacliaxel-eluting stents in real world practice have been published.
METHODS This study is a retrospective analysis of data of all the
patients who received Zilver PTX for FP lesion from February 2013
to October 2014 at MedStar Washington Hospital Center in Washing-
ton, DC. The primary endpoint of this study was primary patency,
deﬁned as a peak systolic velocity ratio < 2.0 by Doppler ultrasound,
or angiographic diameter stenosis < 50%, or freedom from clinically
driven target lesion revascularization.
RESULTS A total of 78 patients received Zilver PTX for FP lesions
in the pre-speciﬁed time period. Of them, 63 had follow-up data
and were included in this study. The mean patient age was
66.39.4 years, and 57.1% of the patients were men. Participants
had a high prevalence of diabetes (49.2%), hypertension (93.7%),
hyperlipidemia (93.7%), previous coronary revascularization
(52.4%), or previous peripheral arterial disease (77.8%). Critical limb
ischemia was present in 25.4% of the patients, Trans-Atlantic Inter-
Society Consensus (TASC) class C or D in 76.2%, in-stent restenosis
(ISR) in 36.5%, and total occlusion in 69.8%. The mean lesion
length was 218.9128.3mm, the mean number of stents was
2.021.0, and total stent length was 189.0128.5 mm. Mean follow-
up was 270.4190.3 days. Primary patency rate at 1 year was 66.7%
by Kaplan-Meier survival curve. When compared with patients with
primary patency at follow-up, those with an adverse outcome had
higher prevalence of TASC II class C or D lesions (100% vs. 68.8%,
p¼0.013), and were more likely to have ISR (66.7% vs. 27.1%,
p¼0.012), longer lesion (291.3138.7 vs. 195.7117.1, p¼0.011), and
incomplete coverage of the lesion (full coverage of lesions: 40% vs.
77.1%, p¼0.011).
CONCLUSIONS Post marketing use of Zilver PTX for the treat-
ment of FP lesions is associated with lower patency rates compared
with clinical trial data. This may be related to the high prevalence of
TASC II class C or D lesions and ISR in real world practice. Future
studies should be more representative of contemporary clinical
practice.
CATEGORIES ENDOVASCULAR: Peripheral Vascular Disease and
Intervention
KEYWORDS Femoropopliteal artery, Paclitaxel-eluting stent, Reste-
nosis, in-stent
TCT-787
Evaluation of Cell Proliferation in Adaptive Neointimal Remodeling
Following Arteriovenous Fistula in a Large Animal Model
Armando Tellez,1 Krista N. Dillon,1 Scott T. Wilson,2 Jan Guerrero,3
Dane A. Brady,1 Will Grundy,1 Joan Wicks,1 Serge D. Rousselle1
1Alizee Pathology, Thurmont, MD; 2MPI Research, Mattawan, MI;
3Celladon Corporation, San Diego, CA
BACKGROUND Arteriovenous ﬁstula (AVF) dysfunction caused by
venous intimal hyperplasia persists as a signiﬁcant threat to AVF long-
term patency. Beyond conventional vascular planimetry we aim to
evaluate the use of cell proliferation markers in neointima in a swine
model of AVF.
METHODS Femoral AVF were surgically performed in nine swine by
anastomosis. AVFs were followed for 3(n¼3) and 90(n¼6) days. At
termination, AVFs were harvested and histological and planimetric
analysis was performed. Immunohistochemistry for cellular prolifer-
ation was performed at the anastomosis levels as well as the arterial
(A) and venous (V) anastomosis side.
RESULTS At 3 days, AVF displayed matching dimensions between V
and A with a vascular area of 13.24.3mm2 in A and 15.19.4 mm2 in
V. By 90 days, the vascular area on V increased by approximately 4-
fold (58.642.5 mm2) while A increased by less than 3-fold
(37.39.4 mm2). These planimetric ratios remained consistent in the
proximal A and distal V at 3 (A¼14.34.1 mm2;V¼36.814.8 mm2) and
90 days (A¼40.212.8 mm2;V¼68.628.2 mm2). At 3 days, percent
area of stenosis (%AS) at the anastomosis was minimal (A¼1.81.5%;
V¼56.1%). However at 90 days, V demonstrated markedly increased
%AS (21.916.5%) compared to A (6.92.9%), reﬂecting V being arte-
rialized. As expected, cell proliferation counts were high at 3 days
evidenced by a high Ki67 index in V (159.2134.7 cells/mm2) and
highest values were recorded in the V distal outﬂow side. Ki67 counts
signiﬁcantly decreased at 90 days (35.222.4 cells/mm2).CONCLUSIONS Proliferation markers (Ki67) provide valuable assess-
ment of vascular response. The AVF swine model provides an ideal
scenario where conventional planimetry data describes the structural
outcome while proliferative markers provide a dynamic picture of the
biological vascular response.
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BACKGROUND There are serious risks associated with untreated pe-
ripheral and visceral arterial thromboembolism. The Penumbra/Indigo
System is a novel, highly trackable and efﬁcient aspiration system in
the peripheral vasculature. Reported herein are the initial results from
the PRISM trial, the ﬁrst multicenter study designed to obtain safety
and effectiveness data in conﬁrmed peripheral or visceral artery
occlusion.
METHODS A total of 55 patients have been enrolled in this retro-
spective trial. In cases of failed thrombolysis, acute ischemia, or pa-
tients with distal emboli due to a prior intervention, thrombectomy
using the Penumbra/Indigo System was implemented. The primary
sites of occlusion were the popliteal (38.9%), peroneal (9.3%), super-
ﬁcial femoral (18.5%), posterior tibial (7.4%), profunda femoris (3.7%),
superior mesenteric (3.7%), anterior tibial (9.3%), renal (3.7%), com-
mon femoral (1.9%), and brachial (1.9%) arteries.
RESULTS The mean patient age was 70.4  12.9 years. At baseline,
96.1% (49/51) patients reported an angiographic TIMI score of 0-1, and
4 patients were unable to be assessed. Before any intervention was
performed, 37.7% (20/53) of patients received only thrombolytic
therapy, 9.4% (5/53) received only mechanical intervention, 7.5% (4/
53) received both therapies, and 45.3% (24/53) had no prior treatment
and were treated with the Penumbra/Indigo Systems as frontline.
Median time from symptom onset to procedure was 5.0 days (IQR 2.0-
24.0). Post-procedure, 96.1% (49/51) of patients were successfully
revascularized to TIMI 2 (39.2%) or TIMI 3 (56.9%). Six patients had
SAEs, none related to the device.
CONCLUSIONS Experience with the Penumbra/Indigo System dem-
onstrates that using thrombo-aspiration for peripheral and visceral
thromboembolism can lead to promising results in safety and effec-
tiveness. This validates possible use across a wide range of applica-
tions in the peripheral vasculature.
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BACKGROUND There are limited data on outcomes of stent-based
treatment of femoropopliteal peripheral artery disease (PAD) in pa-
tients with diabetes mellitus (DM).
METHODS Consecutive patients between January 2006 and March
2015 enrolled in the observational Excellence in Peripheral Artery
Disease (XLPAD) registry (NCT01904851) were analyzed. Index limb
procedures of patients with stent implants were included in the
analysis. Outcomes tracked were major adverse limb events (MALE;
target limb revascularization, surgical revascularization, and un-
planned above-ankle amputation in target limb) and major adverse
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tion, and stroke).
RESULTS A total of 768 procedures from 597 patients were included
in the analysis, with DM comprising 52.9% of the sample. Diabetics
had higher rate of concomitant hypertension (97.8% vs. 86.4%;
p<0.0001), hyperlipidemia (93.3% vs. 81.1%; p<0.0001), coronary ar-
tery disease (75.9% vs. 58.0%; p<0.0001), heart failure (24.6% vs.
14.4%; p¼0.001), and chronic kidney disease (26.4% vs. 6.6%;
p<0.0001) compared to non-diabetics. Mean Rutherford category was
signiﬁcantly higher for diabetics (3.50.9 vs. 3.10.7; p<0.0001) with
higher rates of presenting critical limb ischemia (30.8% vs. 15.6%;
p<0.0001). Although patients with DM had higher rates of heavily
calciﬁed lesions (64.3% vs. 55.5%; p¼0.01), incidence of chronic total
occlusion was lower (58.6% vs. 71.8%; p¼0.001). Kaplan-Meier sur-
vival analysis evidenced signiﬁcantly higher MACE in DM (13.9% vs.
5.7%; p¼0.003) as well as MALE (37.7% vs. 28.0%; p¼0.024) at 12-
months. After adjusting for signiﬁcant differences in baseline and
lesion characteristics, patients with DM were not at a signiﬁcantly
higher risk for experiencing MACE (hazard ratio or HR¼1.60; 95%
conﬁdence interval or CI¼0.80-3.33; p¼0.19; Figure 1A) and MALE
(HR¼1.28; 95% CI¼0.93-1.78; p¼0.14; Figure 1B).CONCLUSIONS Contemporary endovascular treatment of femo-
ropopliteal PAD with stents in patients with DM is associated with
similar limb and cardiovascular outcomes as those without DM,
despite more adverse co-morbid factors and lesion characteristics.
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BACKGROUND The risk of distal embolization (DE) during infrain-
guinal peripheral artery interventions (PAI) is often mitigated with the
use of embolic protection devices. There is limited data on the use of
ﬁlters with the Jetstream (JS) atherectomy device, a rotational cutter
with aspiration capacity. The Nav-6 ﬁlter is uniquely suited for use
with JS due to its wire compatibility and detachment from the ﬁlter,
however this off-label use of the ﬁlter has never been reported.
METHODS Consecutive patients between October 2008 and April 2015
undergoing endovascular infrainguinal PAI with JS were analyzed as
part of the Excellence in Peripheral Artery Disease (XLPAD) registry
(NCT01904851). Patients were divided into 2 subgroups with Nav-6
ﬁlter use vs no ﬁlter use. Descriptive and univariate analysis were
performed.RESULTS 141 patients (mean age 67.810.8 years; 169 lesions) were
included in this study. Nav-6 ﬁlter was used in 82 patients (59%).
Use of a ﬁlter was more frequent for longer lesions (146106 mm vs.
9172 mm; p¼0.006), severe stenosis (95% vs 87%, p¼0.04) and
chronic total occlusion (CTO; 33% vs. 8.3%; p¼0.002). Patients
receiving ﬁlters had longer procedure duration (10251 vs 6641 min)
with higher ﬂuoroscopy times (3116 vs 2110, p<0.001). Use of the
Nav-6 ﬁlter with the JS during PAI was associated with numerically
lower rates of DE (1.8% vs. 8% respectively; p¼0.1). Death and
amputation rates were low and similar in both groups. 12-month
target lesion revascularization rate was higher in the ﬁlter group (22%
vs. 2.7%; 0.02), likely secondary to the more complex lesions treated.
CONCLUSIONS The off-label use of the Nav-6 ﬁlter during JS athe-
rectomy was predominantly used during complex infrainguinal PAI
and was associated with numerically lower number of DE.
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BACKGROUND Although previous studies have reported that the
drug-eluting stent (DES) successfully reduced in-stent restenosis (ISR)
by inhibiting neointimal hyperplasia (NIH) in the coronary artery, the
impact of DES on NIH in the peripheral artery is unclear. This study
sought to investigate the difference of vascular response between
self-expanding bare-metal stent (BMS) and paclitaxel-eluting stent
(PES) for superﬁcial femoral artery (SFA) disease with optical fre-
quency domain imaging (OFDI).
METHODS Consecutive 40 de novo SFA lesions scheduled endovas-
cular therapy (EVT) were randomly assigned 1:1 to receive either BMS
(SMART) or PES (Zilver PTX) implantation. Follow-up angiography
and OFDI examination were conducted six months after EVT to
evaluate vascular response to the stent. Cross-sectional OFDI images
were analyzed at every 5-mm axial interval throughout stented seg-
ments, and stent and lumen borders were manually traced in all image
slices. Neointimal area was calculated as stent area - lumen area.
Stent, lumen, and neointimal volumes were calculated using Simp-
son’s rule. Percent neointimal volume obstruction was calculated as
neointimal volume divided by stent volume. Mean neointimal area
was as neointimal volume divided by stent length.
RESULTS Baseline patient and lesion characteristics were well-
matched between two groups. Total stent length was 96.529.1 mm in
the BMS group and 81.537.6 mm in the PES group (P¼0.17). Follow-
up angiography and OFDI were performed in 16 lesions of the BMS
group and in 16 lesions of the PES group. The binary angiographic ISR
rate was 25.0% in the BMS group and 6.2% in the PES group (P¼0.33).
Percent neointimal volume obstruction was lower in the PES group
compared to the BMS group (29.17.9% vs. 40.210.6%, P<0.01).
Mean neointimal area was smaller in the PES group (7.42.7 mm2 vs.
11.42.7 mm2, P<0.001).
Table. OFDI Findings at 6-month Follow-upBMS (n[16) PES (n[16) P valueNeointimal volume
(mm3)235.1  94.5 115.7  48.1 <0.001Mean neointimal area
(mm2)11.4  2.7 7.4  2.7 <0.001Minimum lumen area
(mm2)10.0  4.1 11.3  2.9 0.32%Neointimal volume
obstruction40.2  10.6 29.1  7.9 <0.01Data given as mean  SD or n (%)
BMS; bare-metal stent, PES; paclitaxel-eluting stent, OFDI; optical frequency domain imaging.
